(Nasdaq:MODD) has shared new data highlighting the use of its insulin pump technology to deliver GLP-1 therapeutics.

VX-880 stem cell therapy led to 92% reduction in insulin use, with 10 out of 12 patients eliminating injections entirely in a ...

Medtronic, Beta Bionics and Tandem Diabetes Care showcased planned patch pumps at the conference, while Senseonics shared ...

“Inhaled insulin can quickly get to the carbohydrates that are in the bloodstream, get them into the cells and out of the ...